Harbour BioMed Launches Élancé Therapeutics to Develop Next-Generation Obesity Treatments

Harbour BioMed has launched a new company called Élancé Therapeutics5.
Élancé Therapeutics is focused on advancing next-generation obesity therapies5.
The company leverages advanced bispecific antibody technology to address key challenges in obesity treatment5.
This launch comes at a time when nearly half of Americans are projected to have obesity by 2030, highlighting the urgent need for effective treatments1.
The obesity treatment landscape is rapidly evolving, with emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 receptor agonists (GLP-1 RAs) heralding a new era of targeted, mechanism-based therapies1.
Élancé Therapeutics was incubated by Harbour BioMed, leveraging the parent company's expertise and resources5.

This development represents a significant step in the ongoing efforts to combat the obesity epidemic, utilizing cutting-edge technology to create more effective and targeted treatments.

Sources:

1. https://www.annualreviews.org/doi/10.1146/annurev-med-043021-014919

5. https://www.morningstar.com/news/pr-newswire/20250312cn39365/harbour-biomed-launches-lanc-therapeutics-to-advance-next-generation-obesity-therapies